Unmet Need
The need for multifactorial therapies
Retinal vascular diseases are a leading cause of vision loss worldwide. Age-related macular degeneration (AMD) alone affects nearly 200 million people, with 10 million experiencing moderate to severe vision loss.1 The neovascular form of AMD (nAMD) accounts for approximately 90% of this vision loss.2
Three dominant angiogenic pathways mediated by VEGF-A, VEGF-C, and Ang-2 contribute to nAMD. Today, the best treatment option for nAMD is repeated monthly injections of anti-VEGF drugs that predominantly target only 1 or 2 of these pathways: VEGF-A and Ang-2.
When only the VEGF-A pathway is treated, both VEGF-C and Ang-2 can become more active in retinal vascular diseases (leading to suboptimal efficacy) or become refractory (requiring more frequent treatment).3
Only ~30% of patients have a form of nAMD that responds optimally to VEGF-A monotherapy.5-7 Therefore, most patients with nAMD might benefit from a treatment that could simultaneously target VEGF-A, VEGF-C, and Ang-2.
*2 months post administration of bevacizumab.
RO-104
RO-104 targets all 3 dominant angiogenic pathways
Developed using our proprietary RevMod Platform, RO-104 is the first and only candidate to singularly target the 3 dominant clinically validated pathways that lead to disease progression in nAMD.
As a first-in-class TriMod biologic, RO-104:
- Singularly binds to VEGF-A, VEGF-C, and Ang-2
- Binds with high, matched affinity
- Demonstrates intended efficacy in established animal models8
Pipeline
A pipeline of discovery and development
Leveraging our proprietary RevMod Platform, RevOpsis is committed to developing a robust pipeline of therapeutic candidates to target prevalent chronic multifactorial ophthalmic diseases, including:
- neovascular age-related macular degeneration (nAMD)
- diabetic macular edema (DME)
- retinal vein occlusion (RVO)
- dry AMD
- uveitic macular edema
- thyroid eye disease.
The RevMod Platform can also be applied across therapeutic categories, including diseases of the immune system, autoimmune diseases, and oncology. We are poised to address unmet needs in millions of patients worldwide.
